サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427982

プロテアソーム阻害剤の世界市場レポート 2024

Proteasome Inhibitors Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
プロテアソーム阻害剤の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

プロテアソーム阻害剤の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には9.2%の年間平均成長率（CAGR）で28億9,000万米ドルに成長すると予想されています。予測期間中に予想される成長は、精密医療アプローチ、次世代阻害剤の開発、ヘルスケアインフラの成長、標的療法の組み合わせ、新興市場での採用の増加に起因すると考えられます。予測期間中に予想される主な動向には、免疫療法、選択的プロテアソーム阻害、半減期の長い阻害剤、経口製剤、耐性がん変異体の治療の組み合わせが含まれます。

プロテアソーム阻害剤市場は、膵臓がんの罹患率の増加により成長する態勢が整っています。膵臓細胞で発生する膵臓がんは、がん細胞の生存と増殖の促進におけるプロテアソームの重要な役割により、プロテアソーム阻害剤の対象となります。 プロテアソーム阻害剤は、がん細胞の生存を妨害し、腫瘍の増殖を阻害し、転移を防ぎます。 2023年 3月の米国臨床腫瘍学会（ASCO）の報告によると、米国では推定64,050人の成人が膵臓がんと診断され、50,550人が死亡しています。 2020年には、世界中で495,773人が膵臓がんと診断され、466,003人が膵臓がんにより死亡しました。この有病率は、プロテアソーム阻害剤市場の成長の原動力であることを強調しています。

プロテアソーム阻害剤市場の成長は、研究開発に対する政府の資金提供を増やすことによってさらに促進されます。政府の資金提供は、科学的調査、臨床試験、医薬品開発を財政的に支援することにより、プロテアソーム阻害剤の調査を進める上で重要な役割を果たしています。たとえば、米国の国立がん研究所は、2023会計年度に73億米ドルの予算を受け、2022年に比べて4億800万米ドル増加しました。この大幅な資金増加は、プロテアソーム阻害剤市場の成長促進に貢献しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のプロテアソーム阻害剤市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ベルケイド
  • キプロリス
  • ニンラロ
  • その他の製品
  • 世界のプロテアソーム阻害剤市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ボルテゾミブ
  • カーフィルゾミブ
  • イクサゾミブ
  • 世界のプロテアソーム阻害剤市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • リンパ腫
  • マントル細胞リンパ腫
  • 多発性骨髄腫
  • 世界のプロテアソーム阻害剤市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界のプロテアソーム阻害剤市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のプロテアソーム阻害剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のプロテアソーム阻害剤市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • プロテアソーム阻害剤市場の競合情勢
  • プロテアソーム阻害剤市場の企業プロファイル
    • Pfizer Inc.
    • Johnson And Johnson
    • AbbVie
    • Novartis AG
    • Merck &Co. Inc.

第31章 その他の大手および革新的な企業

  • Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • AstraZeneca Plc
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Baxter International Inc.
  • Sigma-Aldrich
  • Zydus Pharmaceuticals
  • Onyx Pharmaceuticals Inc.
  • Tocris Bioscience
  • Accuitis Inc.
  • TG Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13826

Proteasome inhibitors constitute a class of drugs designed to disrupt the activity of proteasomes, cellular complexes responsible for the regulated degradation of proteins. These inhibitors find primary application in the treatment of specific types of cancer, particularly multiple myeloma, and certain forms of lymphoma. They have demonstrated significant efficacy in targeting cancer cells and inducing cell death.

The main types of products in proteasome inhibitors include Velcade, Kyprolis, Ninlaro, and others. Velcade, for instance, is the brand name for the prescription drug bortezomib. Bortezomib, as a proteasome inhibitor, is utilized in the treatment of multiple myeloma cancer. Various drugs fall under this category, such as bortezomib, carfilzomib, and ixazomib. Proteasome inhibitors are employed to treat diverse indications, including lymphoma, mantle cell lymphoma, and multiple myeloma. These drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, with end-users primarily consisting of hospitals, specialty clinics, and others.

The proteasome inhibitors market research report is one of a series of new reports from The Business Research Company that provides proteasome inhibitors market statistics, including proteasome inhibitors industry global market size, regional shares, competitors with a proteasome inhibitors market share, detailed proteasome inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the proteasome inhibitors industry. This proteasome inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proteasome inhibitors market size has grown strongly in recent years. It will grow from $1.86 billion in 2023 to $2.03 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The expansion observed in the historical period can be attributed to scientific breakthroughs, advancements in clinical research and trials, FDA approvals, an increase in cancer cases, and innovations in drug delivery methods.

The proteasome inhibitors market size is expected to see strong growth in the next few years. It will grow to $2.89 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The anticipated growth in the forecast period can be attributed to precision medicine approaches, the development of next-generation inhibitors, growth in healthcare infrastructure, combinations of targeted therapies, and increased adoption in emerging markets. Key trends expected in the forecast period include combinations of immunotherapy, selective proteasome inhibition, inhibitors with longer half-lives, oral formulations, and treatments for resistant cancer variants.

The proteasome inhibitors market is poised for growth, driven by the increasing prevalence of pancreatic cancer. Pancreatic cancer, developing in the pancreas cells, is a target for proteasome inhibitors due to the critical role of proteasomes in promoting cancer cell survival and growth. Proteasome inhibitors disrupt cancer cell survival, inhibit tumor growth, and prevent metastasis. According to the American Society of Clinical Oncology (ASCO) reports in March 2023, an estimated 64,050 adults were diagnosed with pancreatic cancer in the US, leading to 50,550 deaths. Globally, 495,773 people were diagnosed, and 466,003 died of pancreatic cancer in 2020. This prevalence underscores the driving force behind the growth of the proteasome inhibitors market.

The growth of the proteasome inhibitors market is further propelled by increasing government funding for research and development. Government funding plays a crucial role in advancing proteasome inhibitor research by financially supporting scientific investigations, clinical trials, and drug development. For example, the National Cancer Institute in the US received a budget of $7.3 billion in fiscal year 2023, a $408 million increase over 2022. This substantial funding boost contributes to driving the growth of the proteasome inhibitors market.

Investments are emerging as a key trend in the proteasome inhibitors market, with major companies investing in the development and commercialization of these inhibitors. In September 2022, QLi5 Therapeutics GmbH, a Germany-based developer of novel proteasome inhibitors, secured a significant investment of $10.96 million from venture capital firms such as SV Investment, KHAN Technology Transfer Fund I, Atinum Investment Co., Ltd., and Daol Investment & Securities Co., Ltd. This funding supports QLi5's efforts to advance its pipeline of distinct proteasome inhibitors for cancer, inflammatory, and autoimmune disorders, contributing to the market's growth.

Major companies in the proteasome inhibitors market are strategically focusing on developing novel generic medications, including single-dose vials. For instance, Dr. Reddy's Laboratories, an India-based pharmaceutical company, launched Bortezomib for Injection, 3.5 mg, a generic equivalent of Velcade (bortezomib) injection. This single-dose vial presentation for subcutaneous or intravenous use enhances treatment options for adult patients with multiple myeloma.

In October 2022, Karyopharm Therapeutics Inc., a US-based pharmaceutical company, collaborated with Bristol-Myers Squibb to assess mezigdomide in patients who have received previous treatments. This collaboration with Bristol-Myers Squibb, a provider of innovative medicines, demonstrates a strategic approach to advancing research and development in the proteasome inhibitors market.

Major companies operating in the proteasome inhibitors market report are Pfizer Inc., Johnson And Johnson, AbbVie, Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Baxter International Inc., Sigma-Aldrich, Zydus Pharmaceuticals, Onyx Pharmaceuticals Inc., Tocris Bioscience, Accuitis Inc., TG Therapeuticsn Inc., QLi5 Therapeutics GmbH, Progenra Inc., Nurix Inc., Cephalon Inc., Cleave Therapeutics, Lifesensors Inc., MimiVax LLC, Apotex Inc.

North America was the largest region in the proteasome inhibitors market in 2023. The regions covered in the proteasome inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the proteasome inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The proteasome inhibitor market consists of sales of marizomib, oprozomib, and delanzomib, epoxyketone proteasome inhibitors, non-peptidic proteasome inhibitors, panobinostat and olaparib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Proteasome Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on proteasome inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for proteasome inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The proteasome inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product: Velcade; Kyprolis; Ninlaro; Other Products
  • 2) By Drugs: Bortezomib; Carfilzomib; Ixazomib
  • 3) By Indication: Lymphoma; Mantle Cell Lymphoma; Multiple Myeloma
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End-User: Hospital; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson; AbbVie; Novartis AG; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Proteasome Inhibitors Market Characteristics

3. Proteasome Inhibitors Market Trends And Strategies

4. Proteasome Inhibitors Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Proteasome Inhibitors Market Size and Growth

  • 5.1. Global Proteasome Inhibitors Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Proteasome Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Proteasome Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Proteasome Inhibitors Market Segmentation

  • 6.1. Global Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Velcade
  • Kyprolis
  • Ninlaro
  • Other Products
  • 6.2. Global Proteasome Inhibitors Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bortezomib
  • Carfilzomib
  • Ixazomib
  • 6.3. Global Proteasome Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lymphoma
  • Mantle Cell Lymphoma
  • Multiple Myeloma
  • 6.4. Global Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.5. Global Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital
  • Specialty Clinics
  • Other End-Users

7. Proteasome Inhibitors Market Regional And Country Analysis

  • 7.1. Global Proteasome Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Proteasome Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Proteasome Inhibitors Market

  • 8.1. Asia-Pacific Proteasome Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Proteasome Inhibitors Market

  • 9.1. China Proteasome Inhibitors Market Overview
  • 9.2. China Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Proteasome Inhibitors Market

  • 10.1. India Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Proteasome Inhibitors Market

  • 11.1. Japan Proteasome Inhibitors Market Overview
  • 11.2. Japan Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Proteasome Inhibitors Market

  • 12.1. Australia Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Proteasome Inhibitors Market

  • 13.1. Indonesia Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Proteasome Inhibitors Market

  • 14.1. South Korea Proteasome Inhibitors Market Overview
  • 14.2. South Korea Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Proteasome Inhibitors Market

  • 15.1. Western Europe Proteasome Inhibitors Market Overview
  • 15.2. Western Europe Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Proteasome Inhibitors Market

  • 16.1. UK Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Proteasome Inhibitors Market

  • 17.1. Germany Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Proteasome Inhibitors Market

  • 18.1. France Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Proteasome Inhibitors Market

  • 19.1. Italy Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Proteasome Inhibitors Market

  • 20.1. Spain Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Proteasome Inhibitors Market

  • 21.1. Eastern Europe Proteasome Inhibitors Market Overview
  • 21.2. Eastern Europe Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Proteasome Inhibitors Market

  • 22.1. Russia Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Proteasome Inhibitors Market

  • 23.1. North America Proteasome Inhibitors Market Overview
  • 23.2. North America Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Proteasome Inhibitors Market

  • 24.1. USA Proteasome Inhibitors Market Overview
  • 24.2. USA Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Proteasome Inhibitors Market

  • 25.1. Canada Proteasome Inhibitors Market Overview
  • 25.2. Canada Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Proteasome Inhibitors Market

  • 26.1. South America Proteasome Inhibitors Market Overview
  • 26.2. South America Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Proteasome Inhibitors Market

  • 27.1. Brazil Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Proteasome Inhibitors Market

  • 28.1. Middle East Proteasome Inhibitors Market Overview
  • 28.2. Middle East Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Proteasome Inhibitors Market

  • 29.1. Africa Proteasome Inhibitors Market Overview
  • 29.2. Africa Proteasome Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Proteasome Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Proteasome Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Proteasome Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. Proteasome Inhibitors Market Competitive Landscape
  • 30.2. Proteasome Inhibitors Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson And Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck & Co. Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Proteasome Inhibitors Market Other Major And Innovative Companies

  • 31.1. Bristol-Myers Squibb Company
  • 31.2. Thermo Fisher Scientific Inc.
  • 31.3. AstraZeneca Plc
  • 31.4. Fresenius Kabi AG
  • 31.5. GlaxoSmithKline PLC
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Eli Lilly and Company
  • 31.8. Amgen Inc.
  • 31.9. Baxter International Inc.
  • 31.10. Sigma-Aldrich
  • 31.11. Zydus Pharmaceuticals
  • 31.12. Onyx Pharmaceuticals Inc.
  • 31.13. Tocris Bioscience
  • 31.14. Accuitis Inc.
  • 31.15. TG Therapeutics Inc.

32. Global Proteasome Inhibitors Market Competitive Benchmarking

33. Global Proteasome Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Proteasome Inhibitors Market

35. Proteasome Inhibitors Market Future Outlook and Potential Analysis

  • 35.1 Proteasome Inhibitors Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Proteasome Inhibitors Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Proteasome Inhibitors Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer